Biosight Closes $46M Series C Financing to Advance Clinical Oncology Programs
AIRPORT CITY, Israel, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today announced the deferred closing of its Series C financing, …